In this study we randomly compared the estradiol eluting stent (17-beta-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-beta-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-beta-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-beta-E eluting stent over the control PC stent.
17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease / Airoldi, Flavio; Di Mario, Carlo; Ribichini, Flavio; Presbitero, Patrizia; Sganzerla, Paolo; Ferrero, Valeria; Vassanelli, Corrado; Briguori, Carlo; Carlino, Mauro; Montorfano, M; Biondi-Zoccai Giuseppe, G. L.; Chieffo, Alaide; Ferrari, Angela; Colombo, Antonio. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - (2005). [10.1016/j.amjcard.2005.04.040]
17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease
Montorfano M;Chieffo Alaide;
2005-01-01
Abstract
In this study we randomly compared the estradiol eluting stent (17-beta-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-beta-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-beta-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-beta-E eluting stent over the control PC stent.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
